What it's for (Indications)
- Mercaptopurine is a purine antimetabolite primarily indicated for the maintenance therapy of acute lymphoblastic leukemia (ALL) in pediatric and adult patients.
- It is utilized as part of combination chemotherapy regimens to prolong remission and improve survival outcomes following induction and consolidation phases of treatment.
- Its efficacy stems from its ability to disrupt DNA and RNA synthesis in rapidly proliferating leukemic cells, thereby preventing their growth and spread.
- While not officially an FDA-approved indication for all formulations, mercaptopurine is also extensively used off-label, and with substantial clinical evidence, in the management of severe inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, where its immunosuppressive properties help to reduce inflammation and maintain remission.
- This broad utility underscores its critical role in both oncology and gastroenterology.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of mercaptopurine is highly individualized, requiring careful titration based on the patient's specific diagnosis, body surface area (BSA), concomitant medications, and most importantly, bone marrow tolerance and hepatic function. For acute lymphoblastic leukemia, a common starting oral dose is typically around 1.5 mg/kg or 50-75 mg/m² daily, adjusted to achieve and maintain target white blood cell and platelet counts while minimizing myelosuppression. Dose modifications are frequently necessary, particularly in patients with reduced activity of thiopurine S-methyltransferase (TPMT), an enzyme crucial for mercaptopurine metabolism. Genetic testing for TPMT polymorphism is strongly recommended prior to initiating therapy to identify individuals at high risk for severe and life-threatening myelotoxicity, necessitating a substantial dose reduction (e.g., 90% reduction) or alternative therapy. Dosage adjustments are also required in patients with renal or hepatic impairment. |
Safety & Warnings
Common Side Effects
- Mercaptopurine is associated with a range of side effects, reflecting its cytotoxic and immunosuppressive mechanisms.
- The most common and dose-limiting adverse effect is myelosuppression, manifesting as leukopenia, thrombocytopenia, and anemia, which necessitates frequent complete blood count monitoring.
- Gastrointestinal disturbances such as nausea, vomiting, anorexia, and mucositis are also frequently reported.
- Hepatotoxicity, presenting as cholestasis, jaundice, or elevations in liver enzymes, is another significant concern, requiring regular liver function tests.
- Less common but serious adverse effects include pancreatitis, particularly in patients with inflammatory bowel disease, and an increased susceptibility to infections due to immunosuppression.
- Long-term use carries a heightened risk of developing secondary malignancies, including lymphomas (especially post-transplant lymphoproliferative disorder), non-melanoma skin cancers, and other solid tumors.
- Hypersensitivity reactions and alopecia may also occur.
Serious Warnings
- Black Box Warning: **Life-threatening Myelosuppression and Hepatotoxicity; Thiopurine S-methyltransferase (TPMT) Deficiency; Secondary Malignancies; Concomitant Use with Allopurinol.** Mercaptopurine is a potent cytotoxic drug and an immunosuppressant that can cause severe, life-threatening myelosuppression, including leukopenia, thrombocytopenia, and anemia. This toxicity is dose-dependent and requires frequent and diligent monitoring of complete blood counts (CBCs) during therapy. Patients receiving mercaptopurine are also at significant risk for hepatotoxicity, which can range from transient elevations in liver enzymes to severe cholestasis, hepatic necrosis, and veno-occlusive disease, potentially leading to liver failure. Liver function tests (LFTs) must be regularly monitored. Individuals with inherited deficiency of the enzyme thiopurine S-methyltransferase (TPMT) are at a substantially increased risk of severe, life-threatening myelosuppression from conventional doses of mercaptopurine due to decreased drug metabolism and increased active metabolite exposure. TPMT genotyping or phenotyping should be performed before initiating mercaptopurine therapy to identify patients at high risk, necessitating a significant dose reduction (e.g., 90%) or consideration of alternative treatment options. Mercaptopurine is also associated with an increased risk of secondary malignancies, including lymphomas (such as hepatosplenic T-cell lymphoma, non-Hodgkin lymphoma), myelodysplastic syndrome, and skin cancers (melanoma and non-melanoma). Patients and prescribers should be vigilant for signs and symptoms of malignancy. Concomitant administration of allopurinol with mercaptopurine significantly increases mercaptopurine plasma concentrations due to inhibition of xanthine oxidase, an enzyme involved in mercaptopurine metabolism. Failure to reduce the mercaptopurine dose (typically by 75% or more) when co-administered with allopurinol can lead to fatal myelosuppression. Therefore, a substantial dose reduction of mercaptopurine is mandatory when used concurrently with allopurinol.
- Mercaptopurine carries significant warnings due to its potent cytotoxic and immunosuppressive effects.
- Patients must undergo rigorous and frequent monitoring of complete blood counts (CBCs) to detect and manage severe myelosuppression (leukopenia, thrombocytopenia, anemia), which can be life-threatening.
- Liver function tests (LFTs) should also be routinely monitored for hepatotoxicity, a common and potentially severe adverse effect.
- Genetic testing for thiopurine S-methyltransferase (TPMT) deficiency is crucial prior to therapy initiation, as individuals with reduced TPMT activity are at a substantially increased risk of severe and life-threatening myelotoxicity from conventional doses, necessitating significant dose reduction.
- Immunosuppression increases the risk of serious infections, including opportunistic infections, and the development of secondary malignancies (e.
- g.
- , non-Hodgkin lymphoma, skin cancers).
- Pancreatitis can occur, especially in patients with inflammatory bowel disease.
- Extreme caution is warranted with concomitant administration of allopurinol, which drastically increases mercaptopurine's bioavailability and requires a substantial mercaptopurine dose reduction (typically 75%).
- Live vaccines should generally be avoided during mercaptopurine therapy.
How it Works (Mechanism of Action)
Mercaptopurine (6-mercaptopurine, 6-MP) is a purine antimetabolite that functions as a cytotoxic and immunosuppressive agent. It is a pro-drug that requires intracellular metabolism, primarily by the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT), to its active thioguanine nucleotide (TGN) metabolites, including 6-thioguanosine monophosphate (6-TGMP), 6-thioguanosine diphosphate (6-TGDP), and 6-thioguanosine triphosphate (6-TGTP). These TGNs are then incorporated into both DNA and RNA, leading to the inhibition of de novo purine synthesis and disruption of nucleic acid function, thereby preventing cell replication and proliferation. This mechanism is particularly effective against rapidly dividing cells, such as malignant lymphocytes in leukemia. Additionally, TGNs modulate cellular signaling pathways, including those involving small GTPases, contributing to its immunosuppressive effects by inhibiting lymphocyte proliferation and function, which is beneficial in autoimmune diseases like inflammatory bowel disease. The primary enzyme involved in its inactivation is thiopurine S-methyltransferase (TPMT), whose genetic variations significantly impact drug metabolism and toxicity.